Rhythm Pharmaceuticals announces reimbursement decision in Italy for IMCIVREE

Rhythm Pharmaceuticals announced that the Italian Medicine Agency, AIFA, approved reimbursement for IMCIVREE for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome, BBS. “We are pleased that AIFA has recognized the need for a precision medicine for obesity and control of hunger in BBS,” said Yann Mazabraud, Executive Vice President and Head of International at Rhythm. “Now families in Italy who are affected by this rare neuroendocrine disease will be able to access the first and only treatment option authorized in the European Union, and we look forward to working with the community in Italy to deliver IMCIVREE to patients as we aim to expand access in Europe country-by-country.”